Amgen has announced that it will begin offering discounts to cash-paying patients as part of its efforts to make medications more affordable. This move comes in response to recent calls from former President Donald Trump, who urged drugmakers to reduce prices and improve access for uninsured and underinsured individuals.
The pharmaceutical company’s new pricing initiative aims to provide financial relief to patients who pay out-of-pocket for their prescriptions, potentially lowering the overall cost of certain medications. Amgen stated that the discounts will be available for select drugs and will be accessible through various channels, including healthcare providers and pharmacies.
This development reflects a broader industry trend of pharmaceutical companies exploring ways to reduce drug prices amidst mounting political pressure and public concern about healthcare affordability. Other drugmakers have also announced similar steps, signaling a potential shift toward more accessible pricing strategies within the industry.
Experts note that while such discounts may provide immediate relief for some patients, broader systemic issues related to drug pricing and healthcare costs still need to be addressed. Policymakers and industry leaders continue to debate plans to lower prices and increase transparency in the pharmaceutical industry.